Prior strategy processes as a key to understanding mega-mergers: The novartis case

European Management Journal

Volumn 20, Issue 3, 2002, Pages 223-234

  Schmidt, Sascha ^a   Rühli, Edwin ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Business level (multilevel) strategy; Longitudinal study; M A; Mega merger; Novartis; Resource allocation processes; Strategy processes

Indexed keywords

EID: 0036318325     PISSN: 02632373     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0263-2373(02)00038-5     Document Type: Article

References (33)

1. Sandoz is reaching a very interesting phase
2. Managing the Resource Allocation Process
3. Strategy formulation - A social and political process
4. The Merger of Ciba and Sandoz to Novartis: An Investor Relation Perspective
5. Resource redeployment following horizontal acquisitions in Europe and North America 1988-1992
6. Annual Report
7. Shareholders' Meeting
8. Shareholders' Meeting
9. Abridged Report 1995
10. Strategischer Plan, 1992-2000
11. Success with generics
12. Learning from high-tech deals
13. Life science living
14. Corporate mergers and acquisitions - One more wave to consider
15. Megamergers
16. Biotechnology - A pioneer technology
17. M&A hits another high
18. Strategy making as iterated processes of resource allocation
19. Comments to Shareholders
20. A Platform for Growth
21. Annual Report, 1996
22. The character and significance of strategy process research
23. What is a processual analysis?
24. The Novartis mega-merger - An intra-organisational evolutionary perspective
25. Megamerger in the Pharmaceutical Industry
26. The Synergy Trap: How Companies Lose the Acquisition Game
27. No further share split this year
28. The Innovation Journey
29. Methods for studying innovative development in the Minnesota Innovation Research Progrma
30. The course is defined
31. The division is on track